ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib

BACKGROUND: ROS1 rearrangements are validated drivers in lung cancer, which have been identified in a small subset (1–2%) of patients with non-small cell lung cancer (NSCLC). To date, 18 fusion genes of ROS1 have been identified in NSCLC. The ALK inhibitor (crizotinib) exhibits therapeutic effect ag...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :BMC Cancer
Главные авторы: Xu, Shuguang, Wang, Wenxian, Xu, Chunwei, Li, Xingliang, Ye, Junhui, Zhu, Youcai, Ge, Ting
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2019
Предметы:
Case Report
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6683537/
https://ncbi.nlm.nih.gov/pubmed/31382924
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-5948-y
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы